Market Update: Merck & Co Inc (NYSE:MRK) – Merck, the American Diabetes Association and America’s Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic

[PR Newswire] – KENILWORTH, N.J., April 27, 2016 /PRNewswire/ — Merck (MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today issued a new challenge to the millions of Americans affected by type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. In 2015, award-winning artist Tim McGraw, celebrated actress S. Epatha Merkerson and chef Leticia Moreinos Schwartz each shared their personal connection to type 2 diabetes. Living with diabetes isn’t easy, and that’s why America’s Diabetes Challenge encourages people with type 2 diabetes to work with their doctor to set and reach their A1C goal.1 The program will aim to identify the most common challenges patients submit and will offer tips to help address them. Read more on this. Merck & Co. Inc. (MRK) , with a current value of $155.69B, ended trading yesterday at $56.04. Looking at today’s market, MRK one day range is $56.01 to $56.32 with the price of the stock fluctuating between $45.69 to $61.70 over the last 52 weeks. Merck (MRK) shares are currently priced at 15.11x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -6.63x earnings multiple for the same period. And for dividend hunters, the company pays shareholders $1.84 per share annually in dividends, yielding 3.24%. According to a consensus of 18 analysts, the earnings estimate of $0.85 per share would be $0.00 worse than the year-ago quarter and a $0.03 sequential increase. The full-year EPS estimate is $3.71 which would be a $0.12 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $9.47 Billion. If reported, that would be a 0.53% increase over the year-ago quarter. Recently, Societe Generale Initiated MRK at Buy (Apr 6, 2016). Previously, BofA/Merrill downgraded MRK from Buy to Neutral. When considering if the stock is under or overvalued, the average price target is $61.65, which is 10.01% above where the stock opened this morning. See more in (NYSE:MRK) Similar Articles: Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting Market Update (NYSE:MRK): Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting Market Update: Merck & Co Inc (NYSE:MRK) – Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.